Harmony Biosciences Holdings Inc. (HRMY) News
Filter HRMY News Items
HRMY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
HRMY News Highlights
- HRMY's 30 day story count now stands at 6.
- Over the past 12 days, the trend for HRMY's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about HRMY are GMAB and RARE.
Latest HRMY News From Around the Web
Below are the latest news stories about HARMONY BIOSCIENCES HOLDINGS INC that investors may wish to consider to help them evaluate HRMY as an investment opportunity.
7 Undervalued Biotech Stocks That are Flying Under the Clinical RadarWith so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. |
Russell 2000 Front-Runners: 3 Stocks to Keep an Eye OnWhile all eyes may be on the usual suspects of market hype and influence, astute investors with a contrarian streak may want to consider Russell 2000 stocks. |
HRMY or GMAB: Which Is the Better Value Stock Right Now?HRMY vs. GMAB: Which Stock Is the Better Value Option? |
HARMONY BIOSCIENCES ANNOUNCES POSITIVE TOPLINE DATA FROM PHASE 2 SIGNAL DETECTION STUDY EVALUATING PITOLISANT IN ADULT PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY) today announced positive topline results from its Phase 2 signal detection study evaluating the safety and efficacy of pitolisant in adult patients with myotonic dystrophy type 1 (DM1). |
16 Most Undervalued Small-Cap Stocks To Buy According To Hedge FundsIn this article, we will take a look at the 16 most undervalued small-cap stocks to buy according to hedge funds. To see more such companies, go directly to 5 Most Undervalued Small-Cap Stocks To Buy According To Hedge Funds. Despite strong signs that the central bank would be ready to hit brakes on its […] |
HARMONY BIOSCIENCES TO PRESENT RESULTS FROM BEHAVIORAL STUDY IN 22Q11.2 DELETION SYNDROME AT AMERICAN COLLEGE OF NEUROPSYCHOPHARMACOLOGY ANNUAL MEETINGHarmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, will present caregiver-reported impacts of 22q11.2 deletion syndrome (22q) and data from the Phase 2 INSPIRE trial at the American College of Neuropsychopharmacology Annual Meeting from December 3-6, 2023. |
Wall Street Analysts Predict a 44.38% Upside in Harmony Biosciences Holdings, Inc. (HRMY): Here's What You Should KnowThe average of price targets set by Wall Street analysts indicates a potential upside of 44.4% in Harmony Biosciences Holdings, Inc. (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
HRMY vs. REGN: Which Stock Is the Better Value Option?HRMY vs. REGN: Which Stock Is the Better Value Option? |
Is Harmony Biosciences Holdings, Inc.'s (NASDAQ:HRMY) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?Most readers would already be aware that Harmony Biosciences Holdings' (NASDAQ:HRMY) stock increased significantly by... |
HARMONY BIOSCIENCES TO PARTICIPATE IN PIPER SANDLER 35th ANNUAL HEALTHCARE CONFERENCEHarmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that Harmony's management team will participate in a fireside chat at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY on Thursday, November 30, 2023, at 9:00 a.m. ET. |